Back to top
more

Radius Recycling, Inc. (RDUS)

(Delayed Data from NSDQ)

$18.14 USD

18.14
359,976

+0.23 (1.28%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $18.13 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Waste Removal Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Radius Recycling (RDUS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Radius Recycling (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Core & Main (CNM) Q4 Earnings Match Estimates

by Zacks Equity Research

Core & Main (CNM) delivered earnings and revenue surprises of 0% and 0.41%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

Quest Resource (QRHC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Quest Resource (QRHC) delivered earnings and revenue surprises of -120% and 6.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ArcelorMittal (MT) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

ArcelorMittal (MT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

by Zacks Equity Research

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

by Zacks Equity Research

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

Radius (RDUS) to Stop Work on Abaloparatide Transdermal System

by Zacks Equity Research

Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.

Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.

Do Options Traders Know Something About Radius Health (RDUS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.

Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

by Zacks Equity Research

Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 26th

by Zacks Equity Research

ISRG, KOP, LPL, NOA, and RDUS have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2021.

Are Options Traders Betting on a Big Move in Radius Health (RDUS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.

Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS

by Zacks Equity Research

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

by Zacks Equity Research

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of -74.07% and -7.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More

by Kinjel Shah

Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.